Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Gambogic Acid as Anticancer Agent: A Review

Version 1 : Received: 2 July 2020 / Approved: 3 July 2020 / Online: 3 July 2020 (09:05:13 CEST)

How to cite: Gilani, S.A.; Imran, M.; Haq, I.; Mehboob, R.; Fatima, W.; Hassan, A. Gambogic Acid as Anticancer Agent: A Review. Preprints 2020, 2020070029 (doi: 10.20944/preprints202007.0029.v1). Gilani, S.A.; Imran, M.; Haq, I.; Mehboob, R.; Fatima, W.; Hassan, A. Gambogic Acid as Anticancer Agent: A Review. Preprints 2020, 2020070029 (doi: 10.20944/preprints202007.0029.v1).

Abstract

Gambogic acid, a common traditional Chinese medicine and widely distributed throughout South China, Vietnam, Cambodia, and Thailand. It is prenylated xanthone which is the significant bioactive compound of gamboge. Gambogic acid is known as a strong apoptotic inducer in cancer cells. It has been found as strong anticancer agent against various types of cancer cells lines such as breast cancer, pancreatic, and cervical cancer. It induces apoptosis, down regulates the anti-apoptotic proteins (survivin and BCL2,) and down regulates the activities of P-glycoprotein in drug sensitive human breast MCF-7 and drug-resistant MCF-7/ADR cells. Similarly, it also exerts alteration in P13K, AKT, p21, MMP-2 &-9, and phosphorylated-AKT expressions. The current review highlights the anticancer and chemo-preventive perspectives of gambogic acid and its mechanistic role against human and animal cancers.

Subject Areas

Gambogic acid; phytochemical; breast cancer; pancreatic cancer; glioma cancer

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.